Fundraising FoxChiesi Ventures
Corporate VCBoston · Seed–Series A · 2 people tracked
Find your way into Chiesi Ventures
Each arrow is one introduction. Sign up to fill in the first one.
Ask Giuseppe Accogli to introduce you to Giacomo Chiesi
You →Giuseppe · together at Chiesi Group →Giacomo
Ask Jamie Chen to introduce you to Arthur M. Pappas
You →Jamie · together at Aura Biosciences →Arthur
Sign up to find every way you can get introduced to Chiesi Ventures
- Your email: who you already know at Chiesi Ventures, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Chiesi Ventures team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Chiesi Ventures is a corporate venture capital firm dedicated to rare and orphan diseases. It seeks to complement the strategic interests of its parent, the Chiesi Group, by backing early-stage development opportunities and treatments for rare diseases. The firm also works to broaden the Chiesi network across Europe and the United States, building relationships with universities, other venture capital investors, rare disease patient organizations, and entrepreneurial companies developing therapies in this space.
Source: firm website, verified Aug 3, 2026.
Team · 2 people
from the firm's website & public directoriesWhat they invest in
from 9 of 9 portfolio companiesBiotech ×9Healthtech ×5Medical Devices ×2Deep Tech ×1
HQs:United States×8Spain×1
Who they back
founder profiles across 9 portfolio companiesFounding team size:solo founder×62 founders×3
Investments · 9 tracked
founders shown can be your intro pathBy year:2018 · 22016 · 12015 · 14 dated
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityPappas CapitalPfizer Venture InvestmentsRidgeback Capital+6 more
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesColumbus Venture PartnersDroia VenturesForesite CapitalJazzya InvestmentsMedicxi+4 more
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsFrazier Life SciencesLongitude CapitalMESA VERDE VENTURE PARTNERSNew Enterprise Associates (NEA)Pappas CapitalRiverVest Venture Partners+4 more
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Board seatGiacomo Chiesi· per SEC Form D
Co-investorsAdvent Life SciencesCTI Life Sciences Fund L.P.Mission Bay CapitalMission BiocapitalRemiges Ventures, Inc.RiverVest Venture Partners+5 more
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtechSan Carlos, US
Anthony P. Ford(Executive Officer, Director)inBenjamin Potter(Executive Officer)Anthony FordinHenry Skinner(Director)Liam Ratcliffe(Director)in
Co-investorsAlta PartnersLongitude Capitalabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation – JJDCNew Leaf Venture Partners+2 more
Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsBay City CapitalPappas CapitalQiming Venture Partners USASolasta VenturesCowen Healthcare InvestmentsEcoR1 Capital+1 more
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersRoche Venture FundYsios Capital+5 more
A biopharmaceutical company developing medicines and vaccines with a focus on clinical research and development for human health.
BiotechSan Diego, US
David Johnson(Executive Officer, Director)Cam Gallagher(Director)Scott L. Glenn(Director)in
Co-investorsDecheng CapitalPappas CapitalSofinnova VenturesVedanta CapitalArix BioscienceOrbiMed+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 3
3 IPOs4D Molecular TherapeuticsNASDAQ: FDMTAura BiosciencesNASDAQ: AURAMirum PharmaceuticalsNASDAQ: MIRM
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Aura Biosciences | 5.1% | $14.00 | Nov 2021 | $20.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Chiesi Ventures made?
- Chiesi Ventures has 9 tracked investments, 3 of which have exited.
- What stage does Chiesi Ventures invest at?
- Chiesi Ventures invests at the Seed, Series A stages.
- What is Chiesi Ventures's typical check size?
- Chiesi Ventures typically writes checks of $5M.
- What sectors does Chiesi Ventures focus on?
- Chiesi Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Chiesi Ventures located?
- Chiesi Ventures is headquartered in Boston, US.
- Does Chiesi Ventures lead rounds?
- Yes, Chiesi Ventures leads investment rounds.
- Who does Chiesi Ventures co-invest with?
- Chiesi Ventures most often shares deals with Pappas Capital, Advent Life Sciences, Longitude Capital, among 38 tracked co-investors.
Similar investors
Investinor AS is a Norwegian investment company that partners with founders, entrepreneurs and other investors to help selected promising companies become world-leading.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
Arboretum Ventures is a Midwest-based venture capital firm focused on the healthcare industry, investing in early-stage companies across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
Life Sciences Greenhouse Investments (LSGI) is an evergreen venture fund that provides early-stage capital and operational support to Pennsylvania life science companies working on drug discovery, diagnostics, devices, and healthcare IT solutions.